Takahashi Miwa, Ono Mihoko, Kajikawa Satoru, Mitori Hikaru, Tsubota Kenjiro
Applied Research & Operations, Astellas Pharma Inc., 21 Miyukigaoka, Tsukuba-shi, Ibaraki 305-8585, Japan.
Astellas Gene Therapies, Inc., 480 Forbes Boulevard, South San Francisco, CA 94080, USA.
J Toxicol Pathol. 2025 Apr;38(2):155-160. doi: 10.1293/tox.2024-0084. Epub 2025 Jan 2.
In liver fibrosis, the possible causes of irreversibility include the accumulation of collagen I during extracellular matrix remodeling, together with the deposition of elastic fibers in later stages. Drug development targeting liver fibrosis should preferably employ models that closely mimic human diseases. To better understand the progress of fibrosis in a cynomolgus monkey liver fibrosis model, we evaluated the time-course of changes in the fibrosis score, collagens, and elastic fibers. The animals were subcutaneously administered thioacetamide twice a week (experiment 1) or once every 2 weeks (experiment 2). Liver tissues were collected at 8 and 16 (experiment 1) or 10 and 20 (experiment 2) weeks of administration, and 12 weeks after withdrawal (experiments 1 and 2). The fibrosis score was evaluated by Masson's trichrome staining. Immunohistochemistry for collagen Ia1, III, and IV, and Elastica van Gieson staining were also performed. Fibrosis was observed from week 8 (experiment 1) or 10 (experiment 2), and in most animals, it progressed during the administration period. After withdrawal, the fibrosis scores tended to decrease. Collagen IV was predominant in the early stage but was replaced by collagen I after 20 weeks in both experiments. Collagen III distributed mostly along with collagen I throughout the study period. The elastic fibers deposition was markedly limited throughout the experiment. Fibrous component examination showed that the main collagen type contributing to fibrosis shifted from collagen IV to I after 20 weeks or later and revealed that the fibrosis status is not fully reflected in the fibrosis score.
在肝纤维化中,不可逆性的可能原因包括细胞外基质重塑过程中I型胶原蛋白的积累,以及后期弹性纤维的沉积。针对肝纤维化的药物开发最好采用能紧密模拟人类疾病的模型。为了更好地了解食蟹猴肝纤维化模型中纤维化的进展情况,我们评估了纤维化评分、胶原蛋白和弹性纤维变化的时间进程。动物每周皮下注射两次硫代乙酰胺(实验1)或每2周注射一次(实验2)。在给药8周和16周(实验1)或10周和20周(实验2)时以及停药后12周(实验1和2)采集肝脏组织。通过Masson三色染色评估纤维化评分。还进行了胶原蛋白Ia1、III和IV的免疫组织化学以及弹性纤维van Gieson染色。在第8周(实验1)或第10周(实验2)观察到纤维化,并且在大多数动物中,纤维化在给药期间进展。停药后,纤维化评分趋于下降。在两个实验中,IV型胶原蛋白在早期占主导,但在20周后被I型胶原蛋白取代。在整个研究期间,III型胶原蛋白大多与I型胶原蛋白一起分布。在整个实验过程中,弹性纤维的沉积明显受限。纤维成分检查表明,在20周或更晚之后,导致纤维化的主要胶原蛋白类型从IV型胶原蛋白转变为I型胶原蛋白,并表明纤维化状态在纤维化评分中并未得到充分反映。